Inflammatory Bowel Diseases · 2018 · 173 citations · 25 references
MedicineObstetricsPharmacologyHigh-risk PregnancyInflammationMaternal-fetal MedicineBirth Outcomes EpidemiologyInflammatory Bowel DiseasePerinatal Risk FactorsPregnancy PharmacologyPrenatal CareUlcerative Colitis PharmacotherapyAdverse Event Reporting RatesJanus Kinase Inhibitor TherapyMaternal Drug SafetyMaternal Exposure EffectsPaternal Exposure EffectsPregnancy In Rheumatoid ArthritisPregnancy Safety InformationRegulatory Safety Databases
Background: Active inflammatory bowel disease increases the risk of adverse pregnancy outcomes. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). As a small molecule, tofacitinib is likely to cross the placental barrier; however, information on the effects of tofacitinib on pregnancy outcomes is limited. We report pregnancy and newborn outcomes among patients in UC clinical studies with prenatal (maternal/paternal) exposure to tofacitinib. Methods: Pregnancies with maternal/paternal exposure to tofacitinib were identified and outcomes reported in 5 tofacitinib UC interventional studies (up to March 2017). Outcomes from tofacitinib rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis interventional studies, and RA noninterventional postapproval safety studies, spontaneous adverse event reporting, and registry data are also reported. Results: Of 1157 patients enrolled in the UC interventional studies, 301 were women of childbearing age. Eleven cases of maternal exposure and 14 cases of paternal exposure to tofacitinib (doses of 5 mg or 10 mg twice daily) before/at the time of conception or during pregnancy were identified. Outcomes included 15 healthy newborns, no fetal deaths, no neonatal deaths, no congenital malformations, 2 spontaneous abortions, and 2 medical terminations. Outcomes across other tofacitinib studies and postmarketing cases were consistent, with a healthy newborn being the most common outcome and no fetal deaths. Conclusions: Based on the limited data available, pregnancy and newborn outcomes among patients with prenatal (maternal/paternal) exposure to tofacitinib in UC studies appear similar to those reported for other tofacitinib clinical study populations and the general population.
25
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn, Chinyu Su, Bruce E. Sands et al. · New England Journal of Medicine · 2017 · 1.7K citations · Full text
Maternal age and fetal loss: population based register linkage study
Anne‐Marie Nybo Andersen · BMJ · 2000 · 1.7K citations · Full text
In utero analysis of fetal growth: a sonographic weight standard.
F P Hadlock, R B Harrist, Juan Martinez‐Poyer · Radiology · 1991 · 1.3K citations
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 939 citations · Full text
Medicine, Immunology, Pharmacology +13